Literature DB >> 8800154

Fibrinolysis, antithrombin III, and protein C in neonates during cardiac operations.

J Petăjă1, K Peltola, H Sairanen, M Leijala, R Kekomäki, E Vahtera, M A Siimes.   

Abstract

Fibrinolysis and coagulation were studied in 10 neonates undergoing cardiac operations for congenital heart defects. Coagulation was activated during cardiopulmonary bypass as evidenced by highly increased prothrombin fragment 1 + 2 levels compared with preoperative values. Prothrombin fragment 1 + 2 levels remained elevated until postoperative day 3. Unlike coagulation, fibrinolysis was not activated during cardiopulmonary bypass but did show late activation on postoperative day 3, as evidenced by elevated levels of the fibrin degradation product D-dimer. Lack of fibrinolytic activation during bypass and its appearance on postoperative day 3 were partly explained by changes observed in tissue plasminogen activator and its inhibitor. During bypass, levels of tissue plasminogen activator and its inhibitor increased by 3.4-fold and 3.2-fold, respectively. In the postoperative period, levels of plasminogen activator inhibitor normalized rapidly whereas tissue plasminogen activator remained elevated, resulting in late fibrinolytic activation on postoperative day 3. In accordance with elevated prothrombin fragment 1 + 2, platelet count, antithrombin III, protein C, prothrombin, and factor VII were decreased on postoperative day 2, indicating ongoing consumptive coagulopathy. Nine patients had antithrombin III and six had protein C levels below age-specific normal ranges, consistent with an acquired deficiency state. Three had central venous thrombosis by postoperative day 4 or 5. In all three, thrombosis was preceded by antithrombin III deficiency, protein C deficiency, and highly elevated plasminogen activator inhibitor (3.7 to 37 times the mean of the other patients) on postoperative days 1 to 3. In conclusion, cardiopulmonary bypass in neonates caused rapid and profound alterations in the coagulation and fibrinolytic systems and initiated consumptive coagulopathy lasting until at least postoperative day 3. Thrombophilic abnormalities in antithrombin III, protein C, and fibrinolysis were frequently found and were associated with serious thrombotic complications.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8800154     DOI: 10.1016/S0022-5223(96)70050-8

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  5 in total

1.  Angiotensin-converting enzyme inhibition alters the inflammatory and fibrinolytic response to cardiopulmonary bypass in children.

Authors:  Gregory A Fleming; Frederic T Billings; Tom M Klein; David P Bichell; Karla G Christian; Mias Pretorius
Journal:  Pediatr Crit Care Med       Date:  2011-09       Impact factor: 3.624

2.  Anticoagulant synergism of heparin and activated protein C in vitro. Role of a novel anticoagulant mechanism of heparin, enhancement of inactivation of factor V by activated protein C.

Authors:  J Petäjä; J A Fernández; A Gruber; J H Griffin
Journal:  J Clin Invest       Date:  1997-06-01       Impact factor: 14.808

3.  Effect of tranexamic acid on blood loss in pediatric cardiac surgery: a randomized trial.

Authors:  Kazuyoshi Shimizu; Yuichiro Toda; Tatsuo Iwasaki; Mamoru Takeuchi; Hiroshi Morimatsu; Moritoki Egi; Tomohiko Suemori; Satoshi Suzuki; Kiyoshi Morita; Shunji Sano
Journal:  J Anesth       Date:  2011-09-24       Impact factor: 2.078

4.  Postoperative chylothorax development is associated with increased incidence and risk profile for central venous thromboses.

Authors:  M A McCulloch; M R Conaway; J A Haizlip; M L Buck; V E Bovbjerg; T R Hoke
Journal:  Pediatr Cardiol       Date:  2007-11-21       Impact factor: 1.655

Review 5.  Risk Factors, Prophylaxis, and Treatment of Venous Thromboembolism in Congenital Heart Disease Patients.

Authors:  Michael Silvey; Leonardo R Brandão
Journal:  Front Pediatr       Date:  2017-06-19       Impact factor: 3.418

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.